DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Hospital Universitario Central de Asturias
Oviedo, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario Central de Asturias (21)
2023
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology
-
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 24, Núm. 11, pp. 1252-1265
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
-
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10
-
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
ESMO Open, Vol. 7, Núm. 2
2021
-
Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy
Cancers, Vol. 13, Núm. 11
-
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib
BJU International, Vol. 128, Núm. 2, pp. 254-261
2020
-
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
BJU International, Vol. 126, Núm. 5, pp. 559-567
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
-
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
2017
-
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer
European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286
-
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific Reports, Vol. 7
-
Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients
Journal of the National Cancer Institute, Vol. 109, Núm. 4
2015
2014
-
Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish expanded access program
Expert Opinion on Drug Safety, Vol. 13, Núm. 9, pp. 1165-1173
2013
2010
-
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)
Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803
-
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1